Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 3Breast Neoplasms 2Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Brain Neoplasms 1Alopecia 1

Interventions

Cyclophosphamide 30N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 21Prednisone 20Etoposide 20Vincristine 16Whole-Body Irradiation 15Doxorubicin 15fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 14romidepsin 13Mycophenolic Acid 12Lenalidomide 12Gemcitabine 12Cyclosporine 10Azacitidine 10Brentuximab Vedotin 9Bortezomib 9Alemtuzumab 8Dexamethasone 7Methotrexate 6Cytarabine 6Busulfan 6Carmustine 5pembrolizumab 4fludarabine 4Vorinostat 4Tacrolimus 4Rituximab 4Melphalan 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Peripheral × Immunoconjugates × Clear all
NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Terminated
1 enrolled 5 charts
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡